Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of chemotherapy-dominated treatment, the FDA approved four drugs for AML in 2017 (Pfizer’s Mylotarg, Novartis’s Rydapt, Agios’s Idhifa, and Jazz’s Vyxeos) and an additional four drugs in 2018 (Agios’s Tibsovo, AbbVie’s Venclexta, Pfizer’s Daurismo, and Astellas’s Xospata).
In light of impressive data for multiple newly approved drugs in AML subpopulations, the treatment paradigm is changing rapidly by shifting toward increasingly targeted and personalized therapies.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of ~100 hematologist-oncologists in the United States.
Key drugs covered: Venclexta, Xospata, Idhifa, Tibsovo, Vyxeos, Daurismo, Mylotarg, Rydapt.